BRAF and colorectal cancer: In melanoma and colorectal cancer lines, LY3009120 has been found to inhibit MEK activation driven by Ras mutants, V600-B-Raf monomers, or non-V600-B-Raf dimers (Peng et al, 2015; Vakana et al, 2017).